Traws Pharma reports Q3 net loss $4.0M; Phase 2 ratutrelvir data expected YE 2025

Traws Pharma, Inc.

2025-Q3 EPS reported $1.53 revenue$2,790,000

Net loss of $4.0M ($0.34 diluted EPS) vs $8.5M ($1.49) in Q3 2024; R&D and G&A expenses down significantly.
Cash and equivalents $6.4M at Sept 30, 2025, down from $21.3M at Dec 31, 2024; runway into Q1 2026.
Acquired key patent from Viriom for $2.6M; intangible assets of $2.6M recorded.
Ratutrelvir Phase 2 studies dosed; topline data from both studies expected by year-end 2025.
Iain Dukes permanently appointed CEO, Charles Parker CFO confirmed Oct 6; John Leaman added to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.